Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT04928092

A Zero Acute Kidney Injury Strategy for Percutaneous Coronary Intervention in Patients With ChronicKidney Disease

A Zero Acute Kidney Injury (Zero-AKI) Strategy for Percutaneous Coronary Intervention in Patients With ChronicKidney Disease

Status
Withdrawn
Phase
Study type
Observational
Enrollment
0 (actual)
Sponsor
Virginia Commonwealth University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to compare the outcomes of Percutaneous Coronary Intervention (PCI) in patients with chronic kidney disease (CKD) using smaller doses of contrast dye that are validated as being at low risk of causing injury to the kidneys, with the larger doses that are traditionally used contemporary practice.

Detailed description

This study will evaluate whether using lower doses of contrast dye leads to lower rates of kidney injury compared to current standard of care. In particular, effort will be taken to maintain the total amount of contrast dye below a scientifically-validated threshold calculated on the basis of each participant renal function. Participants will already be scheduled to undergo a PCI. Because a smaller amount of contrast dye will be used, an intravascular ultrasound (IVUS) will be used to help the doctors see and open the blockages in participant's coronary arteries. IVUS is already used to optimize PCI results, but will be used more extensively in this case. The amount of contrast dye received will be tailored on each participant kidney function. Prospectively enrolled patients will be matched with historical controls who underwent PCI with non-intravascular imaging based approach.

Conditions

Interventions

TypeNameDescription
PROCEDUREStandard of care Ultra Low Contrast PCIPCI using low amounts of contrast media which is standard of care at VCU Medical Center

Timeline

Start date
2022-01-01
Primary completion
2023-03-01
Completion
2023-03-01
First posted
2021-06-16
Last updated
2022-02-04

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT04928092. Inclusion in this directory is not an endorsement.